OncoCyte Stock Price, News & Analysis (NASDAQ:OCX) $3.16 -0.68 (-17.71%) (As of 01:34 PM ET) Add Compare Share Share Today's Range$2.83▼$3.7550-Day Range$2.08▼$4.2652-Week Range$2.08▼$10.00Volume30,293 shsAverage Volume18,591 shsMarket Capitalization$26.10 millionP/E RatioN/ADividend YieldN/APrice Target$3.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media OncoCyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside15.4% Upside$3.87 Price TargetShort InterestBearish2.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.59) to ($3.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.50 out of 5 starsMedical Sector929th out of 960 stocksDiagnostic Substances Industry9th out of 10 stocks 2.3 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.87, OncoCyte has a forecasted upside of 15.4% from its current price of $3.35.Amount of Analyst CoverageOncoCyte has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.67% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in OncoCyte has recently decreased by 1.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 3.2 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OncoCyte this week, compared to 1 article on an average week.MarketBeat Follows1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.94% of the stock of OncoCyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OncoCyte are expected to decrease in the coming year, from ($1.59) to ($3.01) per share.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OncoCyte Stock (NASDAQ:OCX)OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More OCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.comDecember 6, 2023 | finance.yahoo.comOncocyte Begins FDA Submissions Process for VitaGraft Transplant AssaysDecember 8, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. November 18, 2023 | morningstar.comOncoCyte Corp OCXNovember 10, 2023 | finance.yahoo.comOncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comOncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the HorizonNovember 9, 2023 | finance.yahoo.comOncocyte Reports Third Quarter 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comOncocyte to Announce Third Quarter 2023 Financial ResultsDecember 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.September 18, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierSeptember 18, 2023 | finance.yahoo.comOncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierSeptember 6, 2023 | finance.yahoo.comOncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS CoverageAugust 28, 2023 | finance.yahoo.comOncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS CoverageAugust 24, 2023 | nasdaq.comBenchmark Maintains Oncocyte (OCX) Speculative Buy RecommendationAugust 15, 2023 | msn.comPiper Sandler Maintains Oncocyte (OCX) Neutral RecommendationAugust 11, 2023 | msn.comNeedham Maintains Oncocyte (OCX) Buy RecommendationAugust 10, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comOncocyte Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comOncocyte Regains Compliance With Nasdaq Listing RequirementsAugust 9, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Regains Compliance With Nasdaq Listing RequirementsAugust 8, 2023 | finance.yahoo.comOncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 ConferenceAugust 3, 2023 | finance.yahoo.comOncocyte To Announce Second Quarter 2023 Financial ResultsAugust 2, 2023 | msn.comOncocyte (OCX) Price Target Increased by 1900.00% to 7.14July 25, 2023 | finance.yahoo.comVitaGraft Kidney Expands Utility in Recurrent Primary Disease PatientsJuly 25, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Announces 1-For-20 Reverse Stock SplitJuly 24, 2023 | finance.yahoo.comOncocyte Announces 1-For-20 Reverse Stock SplitSee More Headlines Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees75Year FoundedN/APrice Target and Rating Average Stock Price Target$3.87 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+5.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,900,000.00 Net Margins-3,923.58% Pretax Margin-1,427.20% Return on Equity-77.26% Return on Assets-33.66% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$1.46 million Price / Sales20.67 Cash Flow$0.84 per share Price / Cash Flow4.34 Book Value$5.78 per share Price / Book0.63Miscellaneous Outstanding Shares8,261,000Free Float8,101,000Market Cap$30.24 million OptionableOptionable Beta1.81 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joshua Riggs (Age 40)President, CEO & Director Comp: $373.2kMr. James Liu (Age 27)Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Comp: $192.48kDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentMs. Sandra O'DonaldSenior Vice President of Business OperationsDr. Michael D. West Ph.D. (Age 70)Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. Peter HongSecretaryMs. Sara RiordanDirector of Medical EducationMore ExecutivesKey CompetitorsAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCCardio DiagnosticsNASDAQ:CDIOTrinity BiotechNASDAQ:TRIBBiomericaNASDAQ:BMRAView All CompetitorsInsiders & InstitutionsAWM Investment Company Inc.Sold 13,466,382 shares on 11/14/2023Ownership: 8.708%Defender Capital LLC.Sold 2,213,410 shares on 10/23/2023Ownership: 1.390%Alfred D KingsleyBought 1,500 shares on 6/14/2023Total: $6,300.00 ($4.20/share)Pura Vida Investments, LlcBought 33,150 shares on 4/5/2023Total: $198,900.00 ($6.00/share)Broadwood Partners, L.P.Bought 1,341,381 shares on 4/3/2023Total: $8.05 M ($6.00/share)View All Insider TransactionsView All Institutional Transactions OCX Stock Analysis - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price target for 2024? 3 analysts have issued 1 year price objectives for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $3.87 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2023? OncoCyte's stock was trading at $6.4180 at the start of the year. Since then, OCX shares have decreased by 47.8% and is now trading at $3.35. View the best growth stocks for 2023 here. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($1.52) by $0.95. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.40 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%. When did OncoCyte's stock split? OncoCyte's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). Who are OncoCyte's major shareholders? OncoCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (8.71%), Defender Capital LLC. (1.39%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews. View institutional ownership trends. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:OCX) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.